IMU (ASX) Ann: Imugene Capital Raising Presentation

Originally posted by Taureanbull: ↑

Jov88, Another good post. However the common myth here is that the dilution is 20%. If we break down the numbers I get a Dilution of 6.5%. At present there are roughly 6.4bn shares on issue. The Instos and Directors get $35m worth of share at .084 cents. That’s 6.5%. The SPP give most shareholders especially small shareholders the opportunity to buy $30,000 at ~.o84. So roughly another 6.5%. Is that DILUTION or is it topping up capital as a business owner/ part business owner to buy in new assets ? I would definitely say this is increasing a shareholders investment in an increasingly bigger and better company.

So today any shareholder can buy shares at .079. The new IMUOE are convertible before Aug 2026 at .115 cents. Or shareholders can buy shares right now on the open market for .079 cents. I don’t see any dilution or massive discount there. In fact that’s probably fairly priced.

For all the blood curdling screams and plans of revenge coming from the keyboard warriors and armchair experts out there, who have absolutely NO EXPERIENCE in running a start-up , running a Biotech Company. Little to NO experience investing let alone investing in the most difficult sector the stock market , they should take the time to consider what LC has said in the announcements.

This acquisition, is an ORPHAN DRUG which comes with the best DATA PACKAGE of any Allogenic CD19 Directed CarT therapy in the world. It’s passed it’s safety trial with 84 patients. With a very high ORR of 84%. all at the cost of a 6.5% dilution

This amazing deal comes with the highly specialised factory and team to produce the Therapy. This is a requirement that satisfies the FDA requirements to get Marketing Approval. That’s a big item ticked off.

Now IMU owns the whole game. The biggest game in town ONCOLOGY . That’s Solid tumors and liquid tumors. All in one UNIVERSAL VACCINE. Not only that, there’s more. In JUNE a meeting was held with the FDA about progressing this drug to a Registrational trial starting in 2024. What we don’t know at this point , is who was there. Was LC or Dr Jakob DuPont invited along to this meeting? I suspect they were.

What is our next move ? We probably should expect a variation to our Oncarlytics FDA IND to include an arm that uses our new CarT. Now that we have both CF33 Oncovirus and CarT therapies that have passed safety trials we are ready to head for Breakthrough Approval for our Universal Vaccine.

This is so breathtaking the scope and scale! What IMUGENE has achieved in les than 4 years is staggering, if you understand Biotech. Yuman FONG definitely thinks the achievements o PH and LC are amazing, he keeps telling us this. Like dog years , Biotech years are about 5 human years to One biotech year. This will get IMU a spot in the Guinness Book of records. And CEO LC will win the Biotech CEO of the century with this achievement.

For new investors to Biotech, there is a stage in the lifecycle of. Biotech that’s called the “Valley of Death”. All start up Bios must pass through the valley of death before success. If you have read Steini’s post ripping into your Chairman Paul Hopper for the non-performance of his other ASX listed companies CHM and RAD, you will see the effects of travelling thru the valley of death. Unfortunately it’s a real trap for investors. A very high percentage of Biotech’ lose considerable value in the years after list whilst they travel thru the valley of death, costing early holders considerable money, because the punters lose patience and sell. Often leaving pissed off because of the endless cap raises at lower and lower share prices to fund the ongoing development. Then one day in less tha 10% of companies they see huge success and make massive money. Unfortunately for Steini he bought into both CHM and RAD far too early.

It the great news for IMU shareholders is that by November 2023 we will be on the other side of the valley of death and on our way to some serious big rewards. We got two amazing bits of news just this week., We cleared cohort 3 of the IT Monotherapy arm of the Vaxinia Mast Trial with the clear statement from our CEO that she is can’t wait to share the results with us. And secondly that we now own the front runner in the allergenic CD 19 CarT space. And it’s ready and FDA supported for Registrational Trials. IMU is fully funded to complete the development and Breakthrough Approvals phase of the first and only UNIVERSAL VACCINE AGAINST ALL CANCERS.

Just read that last sentence again. And think was all this worth a 6.5% dilution considering the massive uplift in valuation we got handed this week. It’s very important to spend time analysing the underlying value of the assets and IP that you Biotech Investment owns. Making decisions based on the out of control emotions some people get from watching the SP all day will end in tears for certain. Remember this is the hardest sector of the stock market to make successful investments, If you don’t have the money, experience and emotional resilience that’s required YOU WILL LOSE MONEY.. Stop blaming the Chairman for the mistakes YOU made.

Expand

Paul and Lesley

Thanks so much for the update, could you please do the updates on the ASX / company formats?

Thanks

XR

No.	Vol.	Price($)
118	16458707	4.8¢

No.

Vol.

Price($)

118

16458707

4.8¢

Price($)	Vol.	No.
5.0¢	1728214	12

Price($)

Vol.

No.

5.0¢

1728214

No.	Vol.	Price($)
116	16443645	0.048
70	6992075	0.047
37	4755253	0.046
52	5221184	0.045
12	1153236	0.044

No.

Vol.

Price($)

116

16443645

0.048

6992075

0.047

4755253

0.046

5221184

0.045

1153236

0.044

Price($)	Vol.	No.
0.050	1728214	12
0.051	1576328	10
0.052	1753192	11
0.053	1774938	12
0.054	2922460	12

Price($)

Vol.

No.

0.050

1728214

0.051

1576328

0.052

1753192

0.053

1774938

0.054

2922460

(20min delay)
Last 4.9¢		Change 0.000(0.00%)		Mkt cap ! $364.4M

Open	High	Low	Value	Volume
4.9¢	5.0¢	4.8¢	$555.4K	11.34M

Paul and Lesley Thanks so much for the update, could you please...

Superannuation Essentials: Building Wealth for Your Retirement

Kaiser Reef sets up $8M capital raising to boost expansion at A1 gold mine

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

A sex scandal is unlikely to hurt Australia's tech crown jewel – just look at trades

Bigtincan bounces 9% after $409M merger proposal sets stage for Nasdaq listing

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Paul and Lesley Thanks so much for the update, could you please...

Top Stories

Superannuation Essentials: Building Wealth for Your Retirement

Kaiser Reef sets up $8M capital raising to boost expansion at A1 gold mine

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

A sex scandal is unlikely to hurt Australia's tech crown jewel – just look at trades

Bigtincan bounces 9% after $409M merger proposal sets stage for Nasdaq listing

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News